{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:50:03Z","timestamp":1770180603408,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40261-025-01515-x","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T18:38:00Z","timestamp":1768588680000},"page":"207-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab\/Cilgavimab (AZD7442): Results from the PROVENT Sub-study"],"prefix":"10.1007","volume":"46","clinical-trial-number":[{"clinical-trial-number":"nct04625725","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andrew","family":"Ustianowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron J.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"De Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odile","family":"Launay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Veekmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommy","family":"Rampling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Vishnepolsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyantha","family":"Wijewardane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef","family":"Fawadleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilki","family":"Wickramarachchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Sharbaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohini","family":"Beavon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Thissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitalina","family":"Dzutseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth","family":"Seegobin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Streicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Kiazand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark T.","family":"Esser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee-Jah","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"23","key":"1515_CR1","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19. N Engl J Med. 2022;386(23):2188\u2013200.","journal-title":"N Engl J Med"},{"key":"1515_CR2","unstructured":"Nextstrain. Genomic epidemiology of SARS-CoV-2. 2023. https:\/\/nextstrain.org\/ncov\/gisaid\/north-america\/all-time?dmax=2023-01-02&dmin=2022-01-01&f_country=USA&gmin=15. Accessed 8 Nov 2024."},{"issue":"6","key":"1515_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s40121-024-00970-x","volume":"13","author":"MJ Levin","year":"2024","unstructured":"Levin MJ, Ustianowski A, De Wit S, Beavon R, Thissen J, Seegobin S, et al. Efficacy, safety, and pharmacokinetics of AZD7442 (Tixagevimab\/Cilgavimab) for prevention of symptomatic COVID-19: 15-month final analysis of the PROVENT and STORM CHASER trials. Infect Dis Ther. 2024;13(6):1253\u201368.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"1515_CR4","doi-asserted-by":"publisher","first-page":"e0102423","DOI":"10.1128\/mbio.01024-23","volume":"14","author":"Y Young-Xu","year":"2023","unstructured":"Young-Xu Y, Epstein L, Marconi VC, Davey V, Korves C, Zwain G, et al. Tixagevimab\/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data. MBio. 2023;14(4):e0102423.","journal-title":"MBio"},{"issue":"3","key":"1515_CR5","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1093\/cid\/ciac625","volume":"76","author":"J Kertes","year":"2023","unstructured":"Kertes J, Shapiro Ben David S, Engel-Zohar N, Rosen K, Hemo B, Kantor A, et al. Association between AZD7442 (tixagevimab-cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality. Clin Infect Dis. 2023;76(3):e126\u201332.","journal-title":"Clin Infect Dis"},{"key":"1515_CR6","unstructured":"United States Food and Drug Administration. Emergency Use Authorization (EUA) for EVUSHELD Center for Drug Evaluation and Research Review Memorandum. 2023. https:\/\/www.fda.gov\/media\/165226\/download. Accessed 8 Nov 2024."},{"key":"1515_CR7","unstructured":"European Medicines Agency. Assessment report Evusheld, 24 March 2022. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/evusheld-epar-public-assessment-report_en.pdf. Accessed 10 Jan 2025."},{"key":"1515_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01587-23","volume":"68","author":"LE Clegg","year":"2024","unstructured":"Clegg LE, Stepanov O, Schmidt H, Tang W, Zhang H, Webber C, et al. Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab\/cilgavimab) in the prophylaxis and treatment of COVID-19. Antimicrob Agents Chemother. 2024;68:e0158723.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Supplement_2","key":"1515_CR9","doi-asserted-by":"publisher","first-page":"ofad500.464","DOI":"10.1093\/ofid\/ofad500.464","volume":"10","author":"LE Clegg","year":"2023","unstructured":"Clegg LE, Stepanov O, Schmidt H, Reddy VP, Tang W, Gibbs M, et al. Consistency of AZD7442 (cilgavimab\/tixagevimab) pharmacokinetics across prophylaxis and treatment and adult and pediatric participants: application of population pharmacokinetics to enable rapid decision-making during the COVID-19 pandemic. Open Forum Infect Dis. 2023;10(Supplement_2):ofad500.464.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"1515_CR10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/infdis\/jiad014","volume":"227","author":"P Forte-Soto","year":"2023","unstructured":"Forte-Soto P, Albayaty M, Brooks D, Arends RH, Tillinghast J, Aksyuk AA, et al. Safety, tolerability and pharmacokinetics of half-life extended severe acute respiratory syndrome coronavirus 2 neutralizing monoclonal antibodies AZD7442 (tixagevimab-cilgavimab) in healthy adults. J Infect Dis. 2023;227(10):1153\u201363.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"1515_CR11","doi-asserted-by":"publisher","first-page":"ofae631.2119","DOI":"10.1093\/ofid\/ofae631.2119","volume":"12","author":"A Ustianowski","year":"2025","unstructured":"Ustianowski A, Levin MJ, De Wit S, Launay O, Bollen H, Rampling T, et al. P-1960. Safety and pharmacokinetics of long-acting SARS-CoV-2 antibodies tixagevimab\/cilgavimab (AZD7442) are consistent after repeat dosing: results from the PROVENT sub-study. Open Forum Infect Dis. 2025;12(Suppl 1):ofae631.2119.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"1515_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40121-024-00931-4","volume":"13","author":"FDR Hobbs","year":"2024","unstructured":"Hobbs FDR, Montgomery H, Padilla F, Simon-Campos JA, Arbetter D, Seegobin S, et al. Safety, efficacy and pharmacokinetics of AZD7442 (tixagevimab\/cilgavimab) for treatment of mild-to-moderate COVID-19: 15-month final analysis of the TACKLE trial. Infect Dis Ther. 2024;13(3):521\u201333.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1515_CR13","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/S2213-2600(22)00452-0","volume":"11","author":"J Piszczek","year":"2023","unstructured":"Piszczek J, Murthy S, Afra K. Cardiac and vascular serious adverse events following tixagevimab-cilgavimab. Lancet Respir Med. 2023;11(1):e5\u20136.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1515_CR14","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/S2213-2600(22)00450-7","volume":"11","author":"S Maselkar","year":"2023","unstructured":"Maselkar S, Kiazand A, Templeton A, Montgomery H, Esser MT. Cardiac and vascular serious adverse events following tixagevimab-cilgavimab \u2013 author\u2019s reply. Lancet Respir Med. 2023;11(1):e7\u20138.","journal-title":"Lancet Respir Med"},{"issue":"635","key":"1515_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl8124","volume":"14","author":"YM Loo","year":"2022","unstructured":"Loo YM, McTamney PM, Arends RH, Abram ME, Aksyuk AA, Diallo S, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Transl Med. 2022;14(635):eabl8124.","journal-title":"Sci Transl Med"},{"key":"1515_CR16","unstructured":"European Medicines Agency. Kavigale approval (January 20 2025). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/kavigale-epar-medicine-overview_en.pdf. Accessed 4 Apr 2025."},{"issue":"753","key":"1515_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado2817","volume":"16","author":"Y Cai","year":"2024","unstructured":"Cai Y, Diallo S, Rosenthal K, Ren K, Flores DJ, Dippel A, et al. AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults. Sci Transl Med. 2024;16(753):eado2817.","journal-title":"Sci Transl Med"},{"key":"1515_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/S473-3099(24)00804-1","author":"G Haidar","year":"2025","unstructured":"Haidar G, Thomas S, Loubet P, Baker RI, Benfield T, Boonyaratanakornkit J, et al. Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial. Lancet Infect Dis. 2025. https:\/\/doi.org\/10.1016\/S473-3099(24)00804-1.","journal-title":"Lancet Infect Dis"},{"key":"1515_CR19","unstructured":"United States Food and Drug Administration. FDA announces Evusheld is not currently authorized for emergency use in the U.S. (January 26, 2023). 2023. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us. Accessed 8 Nov 2024."},{"key":"1515_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae435","author":"A Bhimraj","year":"2024","unstructured":"Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, et al. Clinical practice guideline update by the infectious diseases society of america on the management of COVID-19: anti-SARS-CoV-2 neutralizing antibody pemivibart for pre-exposure prophylaxis. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae435.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1515_CR21","doi-asserted-by":"publisher","first-page":"ofae631.2128","DOI":"10.1093\/ofid\/ofae631.2128","volume":"12","author":"T Cohen","year":"2025","unstructured":"Cohen T, Rensoli Valzquez M, Munthali C, Tchouakam Kouekam H, Matthews S, Sharbaugh A, et al. P-1969. Safety, immunogenicity, and pharmacokinetics of repeat dosing with AZD7442 (tixagevimab\/cilgavimab): final analysis of the ENDURE phase 2, dose-ranging study in immunocompromised participants. Open Forum Infect Dis. 2025;12(1):ofae631.2128.","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01515-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01515-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01515-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:35:19Z","timestamp":1770179719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01515-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01515-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew Ustianowski reports honoraria\/speaker fees from AstraZeneca, Sanofi, Merck, Janssen, GSK, and Gilead; and advisory boards for Gilead, Merck, Pfizer, and ViiV Healthcare\/GSK. Myron J. Levin reports advisory boards for GSK, Pfizer, Curevo, Moderna, Seqirus, and Dynavax; and research funds from GSK. Stephane De Wit reports honoraria\/speaker fees from AstraZeneca, Sanofi, Merck, Janssen, GSK, and Gilead, and advisory boards for Gilead, Merck, Pfizer, and ViiV Healthcare\/GSK. Odile Launay received honoraria\/speaker fees for advisory boards or lectures from AstraZeneca, Sanofi, Pfizer, Merck, and GSK; and was principal investigator for the AstraZeneca-sponsored PROVENT study in France. Bernard Veekmans, Tommy Rampling, James G. Sullivan, Mark Vishnepolsky, and Priyantha Wijewardane have no disclosures to report. Yousef Fawadleh, Huixia Zhang, Meng Li, Dilki Wickramarachchi, Lauren Hirao, Vitalina Dzutseva, Seth Seegobin, Katie Streicher, Lee-Jah Chang, and Taylor S. Cohen are employees of, and hold or may hold stock in, AstraZeneca. Audrey Sharbaugh, Rohini Beavon, Jesse Thissen, Alexandre Kiazand, John L. Perez,\u00a0and Mark T. Esser, were employees of AstraZeneca at the time the study was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The independent Data Safety Monitoring Board that monitored the PROVENT parent study provided oversight to ensure safe and ethical conduct of the sub-study. The study was performed in accordance with the ethical principles derived from the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Council for Harmonisation Good Clinical Practice Guidelines, and applicable laws and regulations. The protocol, informed consent form, other relevant documents, and any amendments were approved by an institutional review board\/independent ethics committee. All ethics approval details are provided in Online Resource 2.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All PROVENT parent study participants provided written informed consent before enrollment [\n                      \n                      ]. Written informed consent was provided separately for the sub-study before study procedures began.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Interim data from the PROVENT sub-study were presented at the OPTIONS IX Congress, September 26\u201329, 2022, Belfast, UK (Abstract #O-90). Some of the data in this manuscript were presented at the IDWeek 2024 Annual Meeting, October 16\u201319, Los Angeles, CA, USA (Abstract P-1960).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous Presentation"}},{"value":"Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data sharing policy described at\n                      \n                      . Data for studies directly listed on Vivli can be requested through Vivli at\n                      \n                      . Data for studies not listed on Vivli could be requested through Vivli at\n                      \n                      . The AstraZeneca Vivli member page is also available outlining further details:\n                      \n                      .","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Alexandre Kiazand and Lee-Jah Chang designed the study. Jesse Thissen and Seth Seegobin performed the primary data analyses; Jesse Thissen, Seth Seegobin, and Lee-Jah Chang were involved in data curation. Andrew Ustianowski, Myron J. Levin, Stephane De Wit, Odile Launay, Bernard Veekmans, Tommy Rampling, James G. Sullivan, Mark Vishnepolsky, Priyantha Wijewardane, Alexandre Kiazand, and Mark T. Esser were involved in data collection. Audrey Sharbaugh, Alexandre Kiazand, Mark T. Esser, Lee-Jah Chang, and Taylor S. Cohen provided supervision. Mark T. Esser was involved in project administration and funding acquisition. All authors were involved in writing the original draft of the manuscript and in the reviewing and editing of subsequent drafts and approved the final draft of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}